Key features and details
- Rabbit polyclonal to TRAIL
- Suitable for: IHC-P, WB
- Reacts with: Human
- Isotype: IgG
保存方法Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
バッファーPreservative: 0.02% Sodium azide
Concentration information loading...
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab2056 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 20 µg/ml.|
|WB||1/500. Detects a band of approximately 32 kDa.Can be blocked with TRAIL peptide (ab7867).
Gives a 32 kD band which represents the membrane-bound form of TRAIL.
機能Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.
組織特異性Widespread; most predominant in spleen, lung and prostate.
配列類似性Belongs to the tumor necrosis factor family.
- Information by UniProt
- Apo 2 ligand antibody
- APO 2L antibody
- Apo-2 ligand antibody
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) of human brain tissue staining TRAIL with ab2056 at 20µg/ml
Western Blot of human brain lysate labeling TRAIL with Anti-TRAIL antibody (ab2056) at (1) 2.5 and (2) 5 µg/ml.
Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein including extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein containing extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml.
Immunohistochemistry of TRAIL in human brain tissue with TRAIL antibody at 20 µg/ml.
ab2056 は 3 報の論文で使用されています。
- Melendez ME et al. Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations. Oncotarget 9:27233-27241 (2018). PubMed: 29930761
- Ludwig S et al. Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer. Clin Cancer Res 23:4843-4854 (2017). PubMed: 28400428
- Kawano Y et al. TRAIL produced from multiple myeloma cells is associated with osteolytic markers. Oncol Rep 27:39-44 (2012). PubMed: 21993926